Axsome Therapeutics Financials

AXSM Stock  USD 99.65  2.62  2.70%   
Based on the key indicators related to Axsome Therapeutics' liquidity, profitability, solvency, and operating efficiency, Axsome Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Axsome Therapeutics' Cash is very stable compared to the past year. As of the 29th of November 2024, Cash And Short Term Investments is likely to grow to about 405.5 M, though Retained Earnings are likely to grow to (793.8 M). Key indicators impacting Axsome Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio5.833.6316
Way Up
Pretty Stable
Investors should never underestimate Axsome Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Axsome Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Axsome Therapeutics.

Net Income

(227.28 Million)

  
Understanding current and past Axsome Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Axsome Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Axsome Therapeutics' assets may result in an increase in income on the income statement.

Axsome Therapeutics Earnings Geography

Axsome Therapeutics Stock Summary

Axsome Therapeutics competes with Incyte, Sarepta Therapeutics, ACADIA Pharmaceuticals, Viking Therapeutics, and Madrigal Pharmaceuticals. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS05464T1043
CUSIP05464T104
LocationNew York; U.S.A
Business AddressOne World Trade
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.axsome.com
Phone212 332 3241
CurrencyUSD - US Dollar

Axsome Therapeutics Key Financial Ratios

Axsome Therapeutics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets220.5M186.1M(338.4M)331.5M588.2M617.6M
Other Current Liab683.2K8.7M9.3M57.5M95.6M100.4M
Net Debt(200.0M)(133.8M)(36.8M)(106.2M)(199.8M)(189.8M)
Retained Earnings(175.9M)(278.8M)(409.2M)(596.3M)(835.6M)(793.8M)
Accounts Payable10.9M13.5M13.1M38.6M40.7M42.7M
Cash220.0M183.9M86.5M200.8M386.2M405.5M
Other Current Assets413.1K148.4K45.3K5.6M8.1M8.5M
Total Liab41.8M72.3M70.8M221.9M397.3M417.1M
Total Current Assets220.4M184.0M86.5M245.6M504.3M529.5M
Short Term Debt2.6M1.2M620.7K425K2.5M1.4M
Common Stock3.7K3.7K3.8K4.4K5K3.2K
Net Tangible Assets178.7M113.8M15.6M39.6M45.5M52.6M
Other Assets139.9K2.1M(426.1M)14.7M13.2M13.9M
Long Term Debt17.3M48.3M49.1M94.3M178.1M187.0M
Long Term Debt Total3.6M17.3M48.3M49.1M56.5M59.3M
Capital Surpluse108.5M354.6M392.6M424.8M488.5M264.6M
Net Invested Capital198.7M162.1M64.7M203.8M369.0M387.5M
Net Working Capital195.9M160.6M63.5M149.1M365.4M383.7M
Capital Stock3.7K3.7K3.8K4.4K5K4.3K

Axsome Therapeutics Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense1.2M2.6M5.7M7.3M6.5M6.8M
Operating Income(67.2M)(99.1M)(124.7M)(176.5M)(231.8M)(220.2M)
Ebit(67.1M)(99.1M)(124.7M)(179.8M)(231.8M)(220.2M)
Research Development53.6M70.2M58.1M57.9M97.9M102.8M
Ebitda(67.1M)(99.1M)(123.6M)(174.2M)(225.0M)(213.7M)
Income Before Tax(68.3M)(102.9M)(130.4M)(187.1M)(238.3M)(226.4M)
Net Income(69.7M)(105.4M)(134.9M)(197.8M)(239.2M)(227.3M)
Income Tax Expense1.3M2.5M4.5M10.6M960K912K
Gross Profit(37.3K)(77.7K)(1.2M)44.8M244.5M256.8M
Cost Of Revenue37.3K77.7K1.2M5.2M26.1M27.4M
Net Interest Income(1.2M)(2.6M)(5.7M)(7.3M)(6.5M)(6.1M)

Axsome Therapeutics Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash206.0M(36.1M)(97.4M)114.4M185.4M194.6M
Free Cash Flow(46.4M)(78.5M)(108.5M)(117.2M)(145.7M)(138.4M)
Other Non Cash Items650.0K8.0M(104.6K)3.7M53.1M55.8M
Capital Expenditures16.1K45.9K307.5K702.1K582K611.1K
Net Income(68.3M)(102.9M)(130.4M)(187.1M)(239.2M)(227.3M)
End Period Cash Flow220.0M183.9M86.5M200.8M386.2M405.5M
Net Borrowings12.8M27.2M(309.3K)45M51.8M54.3M
Depreciation37.3K77.7K1.2M5.6M6.8M7.2M
Change To Netincome6.1M16.0M20.8M39.9M45.9M48.2M
Investments(16.1K)(45.9K)(307.5K)(53.7M)(582K)(611.1K)

Axsome Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Axsome Therapeutics's current stock value. Our valuation model uses many indicators to compare Axsome Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Axsome Therapeutics competition to find correlations between indicators driving Axsome Therapeutics's intrinsic value. More Info.
Axsome Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Axsome Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Axsome Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Axsome Therapeutics Systematic Risk

Axsome Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Axsome Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Axsome Therapeutics correlated with the market. If Beta is less than 0 Axsome Therapeutics generally moves in the opposite direction as compared to the market. If Axsome Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Axsome Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Axsome Therapeutics is generally in the same direction as the market. If Beta > 1 Axsome Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Axsome Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Axsome Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Axsome Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(1.7)

At this time, Axsome Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year.

Axsome Therapeutics November 29, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Axsome Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Axsome Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Axsome Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Axsome Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Axsome Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.